LAS VEGAS, MIAMI and BUENOS AIRES, Argentina, May 9, 2011 /PRNewswire/ -- Cord Blood America, Inc. (http://www.cordblood-america.com) (OTC Bulletin Board: CBAID), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that Biocordcell Argentina S.A. (BioCells, Inc.) is opening an office in Miami, Florida and 5 new offices in Argentina. CBAI owns 50.1 percent of the profitable Argentina stem cell storage company, which also is developing affiliates throughout South America.
"The Latin American population in Miami is underserved in being provided this important medical procedure and BioCells sees an excellent opportunity to develop a strong affiliate in this major U.S. city," said Matthew Schissler, Cord Blood America CEO and co-founder. The stem cells will be stored at Cord Blood America's state-of-the-art facility in Las Vegas. In Argentina, many great cities will now have BioCells coverage.
BioCells is headquartered in Argentina and is developing affiliates throughout Latin America. Its laboratory and headquarters are in Buenos Aires. The company posted estimated revenues of $1.45 million (U.S.) in 2010. BioCells also announced that it has obtained the prestigious ISO 9001:2008 quality certification on its laboratory procedures for processing and long-term storage of umbilical cord blood stem cells. This is a quality management standard used to establish, improve and certify the organization's process-based quality management system.
"This achievement confirms the high-quality work done by BioCells and affirms it is achieving quality service focused on its clients," Mr. Schissler said.
About Cord Blood America
Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.
CONTACT:Paul KnopickE & E Communications949/[email protected]
Safe Harbor: This press release contains forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies and expectations, are generally identifiable by use of the words "may," "will," "should," "expect," "anticipate," "estimate," "believe," "intend" or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned that such forward looking statements should not be construed as a guarantee or assurance of future performance or results. Actual events or results may differ materially from those discussed in forward-looking statements as a result of various factors. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained herein will in fact occur. These forward-looking statements are based on current expectations, and the Company assumes no obligation to update this information. Readers are urged to carefully review and consider the various disclosures made by the Company in its Form 10-K and in the Company's other reports filed with the Securities and Exchange Commission that discuss certain of the risks and factors that may affect the Company and its business.
SOURCE Cord Blood America, Inc.
Advertisement
"The Latin American population in Miami is underserved in being provided this important medical procedure and BioCells sees an excellent opportunity to develop a strong affiliate in this major U.S. city," said Matthew Schissler, Cord Blood America CEO and co-founder. The stem cells will be stored at Cord Blood America's state-of-the-art facility in Las Vegas. In Argentina, many great cities will now have BioCells coverage.
Advertisement
BioCells is headquartered in Argentina and is developing affiliates throughout Latin America. Its laboratory and headquarters are in Buenos Aires. The company posted estimated revenues of $1.45 million (U.S.) in 2010. BioCells also announced that it has obtained the prestigious ISO 9001:2008 quality certification on its laboratory procedures for processing and long-term storage of umbilical cord blood stem cells. This is a quality management standard used to establish, improve and certify the organization's process-based quality management system.
"This achievement confirms the high-quality work done by BioCells and affirms it is achieving quality service focused on its clients," Mr. Schissler said.
About Cord Blood America
Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.
CONTACT:Paul KnopickE & E Communications949/[email protected]
Safe Harbor: This press release contains forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies and expectations, are generally identifiable by use of the words "may," "will," "should," "expect," "anticipate," "estimate," "believe," "intend" or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned that such forward looking statements should not be construed as a guarantee or assurance of future performance or results. Actual events or results may differ materially from those discussed in forward-looking statements as a result of various factors. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained herein will in fact occur. These forward-looking statements are based on current expectations, and the Company assumes no obligation to update this information. Readers are urged to carefully review and consider the various disclosures made by the Company in its Form 10-K and in the Company's other reports filed with the Securities and Exchange Commission that discuss certain of the risks and factors that may affect the Company and its business.
SOURCE Cord Blood America, Inc.
